Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk

Scott Baltic  |  January 22, 2018

NEW YORK (Reuters Health)—Use of epidural steroid injections (ESIs) “should be approached with prudence,” particularly in patients who are at risk for osteoporotic fractures, such as women of postmenopausal age, according to authors of a systematic review.

Although the literature presents a mixed picture, ESIs in doses as low as 80 mg methylprednisolone equivalents seem to reduce bone mineral density (BMD), both locally (in the lumbar spine) and systemically (in the femoral neck), and ESIs also increase the risk of vertebral fracture, the researchers conclude. They recommend that use of an anti-osteoporotic medication be considered before giving an ESI.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The authors believe that their report, published online Jan. 2 in Pain Medicine, is the first systematic review of all available studies about ESIs’ effects on BMD and vertebral fracture risk.1

“The risk of fracture suggested by these studies is overall quite small, likely not outweighing the potential benefits from pain relief provided by these injections for the majority of patients,” corresponding author Dr. Mohamad Bydon of Mayo Clinic in Rochester, Minn., tells Reuters Health by email.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Nonetheless, he adds, “at this time, there is not enough evidence to provide clinical practice guidelines recommending which patients with known risk factors for diminished BMD are safe candidates for repeated ESIs.”

The new review encompassed eight studies involving 7,233 patients (mean ages, 49 to 74) with average follow-ups of 6 to 60 months. The steroids included triamcinolone, dexamethasone and methylprednisolone; the mean number of injections ranged from 1 to 14.7, with an average cumulative dose between 80 mg and 8,130 mg of methylprednisolone equivalents.

“Significant reductions in BMD” were associated with a cumulative methylprednisolone equivalents dose of 200 mg over one year and 400 mg over three years. However, such reductions were not found with methylprednisolone equivalent doses of <200 mg for postmenopausal women or of at least 3 grams for healthy men.

Overall, the risk of osteopenia and osteoporosis was lower in patients who were also receiving anti-osteoporotic medication.

The report also notes that the reviewed studies “suggest that adverse outcomes in terms of vertebral fracture risk or compromised BMD may differ considerably between men and women, although this has never been directly studied.”

To mitigate systemic effects, including fracture risk, several institutions, including the Mayo Clinic, do not administer more than three to four spinal injections in a given year, Dr. Bydon says.

In discussions with patients about the risks, benefits and alternative to ESIs, he adds, “factors such as older age, low bone density, or history of fracture should be considered. … But if over-administration of steroid increases the risk of injury, such as fracture, we may need to consider which patients are at higher risk for adverse outcomes with repeated doses of steroid.”

“It is also important to consider other (non-epidural) injected steroids the patient may receive, as large joint injections, for example, may contribute to any systemic effect on fracture risk as well as other endocrine side effects,” Dr. Bydon cautions.

This study’s findings are “consistent with known effects of corticosteroids on bone,” Dr. Roger Chou, director of the Pacific Northwest Evidence-based Practice Center at Oregon Health & Science University, told Reuters Health by email.

He notes, however, the uncertainty about whether ESIs have negative bone effects, “[because] the effects of corticosteroids are presumed to be mostly from systemic effects, and most of the corticosteroid that is injected into the epidural space is probably not having systemic effects; rather it has local effects in the epidural space.”

Dr. Chou cautions that all the studies in this review were observational. “The results should also be interpreted in the context of studies showing that the benefits of epidural steroid injections are small and short-lived,” he says.


Reference

  1. Kerezoudis P, Rinaldo L, Alvi MA, et al. The effect of epidural steroid injections on bone mineral density and vertebral fracture risk: A systematic review and critical appraisal of current literature. Pain Med. 2018 Jan 2. doi: 10.1093/pm/pnx324. [Epub ahead of print]

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)epidural steroid injectionsfracture riskFracturesOsteoporosis

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

    November 14, 2021

    Figure 1. Peripheral blood smear showing a large granular lymphocyte in a 53-year-old Hispanic man. Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL…

    Reading Rheum

    March 1, 2007

    Handpicked Reviews of Contemporary Literature

    Imaging in Ankylosing Spondylitis

    April 1, 2015

    MRI inflammation, fat and new bone formation in the sacroiliac joints, spine in patients with AS

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences